Ponezumab clinical trials
Also written PF-04360365.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses ponezumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses ponezumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00945672Written as PF-04360365 10 mg/kg
- Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00722046Written as PF-04360365 0.1 mg/kg
- Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid AngiopathyCompletedPhase 2PfizerNCT01821118Written as Ponezumab
- Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy VolunteersCompletedPhase 1PfizerNCT01005862Written as PF-04360365
- Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's DiseaseCompletedPhase 1PfizerNCT01125631Written as PF-04360365 8.5 mg/kg
- A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's DiseaseCompletedPhase 1PfizerNCT00607308Written as PF-04360365
- A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's DiseaseCompletedPhase 1PfizerNCT00455000Written as PF-04360365
- Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 1PfizerNCT00733642Written as PF-04360365 1 mg/kg
Codes
What other systems call ponezumab · ClinicalTrials.gg INT006073
- MeSH (NLM) C572721ponezumabOne source NLM
- UNII (FDA) 1TG15H1XE9PONEZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7227765PonezumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97941PonezumabOne source FDA
- DrugBank DB15135One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572721 | ponezumab | One source NLM |
| UNII (FDA) | 1TG15H1XE9 | PONEZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7227765 | Ponezumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97941 | Ponezumab | One source FDA |
| DrugBank | DB15135 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.